Kutsch Nadine, Marks Reinhard, Ratei Richard, Held Thomas K, Schmidt-Hieber Martin
Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
Clinic for Hematology, Oncology and Stem Cell Transplantation, University Hospital of Freiburg, Freiburg, Germany.
Biomark Insights. 2015 Aug 16;10(Suppl 3):15-23. doi: 10.4137/BMI.S22434. eCollection 2015.
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically or be activated within signal transduction pathways leading to tumor survival and growth. Among others, Bruton's tyrosine kinase (Btk) is of particular interest as a potential therapeutic target. Btk is stimulated by B-cell receptor signaling and activates different transcription factors such as nuclear factor κB. The Btk inhibitor ibrutinib has been approved for the treatment of chronic lymphocytic leukemia and mantle-cell lymphoma recently. Numerous clinical trials evaluating this agent in different combinations (eg, with rituximab or classical chemotherapeutic agents) as a treatment option for aggressive and indolent lymphoma are under way. Here, we summarize the role of tyrosine kinase inhibitors in the treatment of indolent and other non-Hodgkin lymphomas (eg, mantle-cell lymphoma).
靶向酪氨酸激酶是针对不同恶性肿瘤的一种高度特异性治疗方法。这也包括非霍奇金淋巴瘤，因为众所周知这些酶经常参与淋巴瘤的发生。在此，酪氨酸激酶可能在本质上失调，或者在导致肿瘤存活和生长的信号转导途径中被激活。其中，布鲁顿酪氨酸激酶（Btk）作为一种潜在的治疗靶点特别受关注。Btk受B细胞受体信号刺激，并激活不同的转录因子，如核因子κB。Btk抑制剂伊布替尼最近已被批准用于治疗慢性淋巴细胞白血病和套细胞淋巴瘤。目前正在进行大量临床试验，评估该药物以不同组合（如与利妥昔单抗或经典化疗药物联合）作为侵袭性和惰性淋巴瘤治疗选择的效果。在此，我们总结酪氨酸激酶抑制剂在惰性及其他非霍奇金淋巴瘤（如套细胞淋巴瘤）治疗中的作用。
